Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, Jansen JH. van de Loosdrecht AA, et al. Among authors: legdeur mc. Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31. Leukemia. 2024. PMID: 38297135 Free PMC article. Clinical Trial.
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Huls G. Hilberink JR, et al. Among authors: legdeur mc. Blood Cancer J. 2023 Jun 19;13(1):93. doi: 10.1038/s41408-023-00850-6. Blood Cancer J. 2023. PMID: 37336890 Free PMC article.
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJ. Janssen JJWM, et al. Among authors: legdeur mcjc. Leukemia. 2022 Sep;36(9):2189-2195. doi: 10.1038/s41375-022-01657-3. Epub 2022 Jul 22. Leukemia. 2022. PMID: 35869267 Clinical Trial.
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Rijneveld AW, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, Halkes CJM, Fijnheer R, Havelange V, van Sluis GL, Legdeur MC, Deeren D, Gadisseur A, Sinnige HAM, Breems DA, Jaspers A, Legrand O, Terpstra WE, Boersma RS, Mazure D, Triffet A, Tick LW, Beel K, Maertens JA, Beverloo HB, Bakkus M, Homburg CHE, de Haas V, van der Velden VHJ, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Rijneveld AW, et al. Among authors: legdeur mc. Blood Adv. 2022 Feb 22;6(4):1115-1125. doi: 10.1182/bloodadvances.2021005624. Blood Adv. 2022. PMID: 34883506 Free PMC article. Clinical Trial.
Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.
Pijnappel EN, Wassenaar NPM, Gurney-Champion OJ, Klaassen R, van der Lee K, Pleunis-van Empel MCH, Richel DJ, Legdeur MC, Nederveen AJ, van Laarhoven HWM, Wilmink JW. Pijnappel EN, et al. Among authors: legdeur mc. Cancers (Basel). 2021 Sep 28;13(19):4869. doi: 10.3390/cancers13194869. Cancers (Basel). 2021. PMID: 34638351 Free PMC article.
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, Ossenkoppele GJ. Löwenberg B, et al. Blood Adv. 2021 Feb 23;5(4):1110-1121. doi: 10.1182/bloodadvances.2020003855. Blood Adv. 2021. PMID: 33616652 Free PMC article. Clinical Trial.
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, Borne PVD, Breems D, Brouwer R, Chalandon Y, Deeren D, Efthymiou A, Gjertsen BT, Graux C, Gregor M, Heim D, Hess U, Hoogendoorn M, Jaspers A, Jie A, Jongen-Lavrencic M, Klein S, Klift MV, Kuball J, Lammeren-Venema DV, Legdeur MC, Loosdrecht AV, Maertens J, Kooy MVM, Moors I, Nijziel M, Obbergh FV, Oosterveld M, Pabst T, Poel MV, Sinnige H, Spertini O, Terpstra W, Tick L, Velden WV, Vekemans MC, Vellenga E, Weerdt O, Westerweel P, Stüssi G, Norden YV, Ossenkoppele G. Janssen J, et al. Among authors: legdeur mc. Cancers (Basel). 2021 Feb 7;13(4):672. doi: 10.3390/cancers13040672. Cancers (Basel). 2021. PMID: 33562393 Free PMC article.
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Huls G, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, van Zeventer I, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ. Huls G, et al. Among authors: legdeur mc. Blood Adv. 2020 Sep 22;4(18):4267-4277. doi: 10.1182/bloodadvances.2020002846. Blood Adv. 2020. PMID: 32915972 Free PMC article. Clinical Trial.
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Ossenkoppele GJ, et al. Leukemia. 2020 Oct;34(10):2820. doi: 10.1038/s41375-020-0994-7. Leukemia. 2020. PMID: 32733013
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Ossenkoppele GJ, et al. Leukemia. 2020 Jul;34(7):1751-1759. doi: 10.1038/s41375-020-0725-0. Epub 2020 Feb 4. Leukemia. 2020. PMID: 32020044 Clinical Trial.
30 results